EGFR and breast carcinoma: EGFR has long been in spotlight as a reasonable target molecule for developing antitumor strategies, since its aberrant activation by increased expression of a constitutively activated truncated variant EGFRvIII or itself is implicated in the development and progression of a broad range of solid cancer diseases including breast cancer [50].